[Comment] Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC

00:00 - 13 Jan 2026

The management of advanced non-small-cell lung cancer (NSCLC) with activating mutations in EGFR has evolved over the past 20 years. Whether used alone, or in combination with chemotherapy or the bispecific anti-EGFR MET antibody amivantamab, third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, are the backbone of treatment. Repeat tissue biopsies following progression on EGFR TKIs identify targetable genomic and histological changes driving TKI resistance in a subset of patients.